Skip to content

Latest Post

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label India’s First Zika Vaccine Wins CDSCO Panel Nod for Phase I Trial Rezatapopt Ovarian Cancer Data: p53 Pill Shrinks Tumours in 48% of Platinum-Resistant Patients GLP-1 Heart Failure Study: Semaglutide and Tirzepatide Remodel Weak Hearts Beyond Weight Loss Manipur Liquor Tragedy: Toll Hits 15 as 300+ Treated for Suspected Methanol Poisoning
  • Sun. Nov 22nd, 2026
MedGadget.in logo – medical technology news and healthcare technology insights

  • Home
  • About Us
  • Author
  • Contact Us
Pharmaceutical

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label

November 21, 2026 Simone Lamb

The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here…

Clinical Trials

India’s First Zika Vaccine Wins CDSCO Panel Nod for Phase I Trial

November 21, 2026 Simone Lamb

A CDSCO expert panel recommended a Phase I trial of Indian Immunologicals' live attenuated Zika vaccine, developed with Griffith University and funded by ICMR.

Clinical Trials

Rezatapopt Ovarian Cancer Data: p53 Pill Shrinks Tumours in 48% of Platinum-Resistant Patients

November 21, 2026 Simone Lamb

PMV Pharmaceuticals' rezatapopt produced a 48% response rate in platinum-resistant ovarian cancer with TP53 Y220C in the pivotal PYNNACLE trial, with an FDA filing planned…

Clinical Trials

GLP-1 Heart Failure Study: Semaglutide and Tirzepatide Remodel Weak Hearts Beyond Weight Loss

November 21, 2026 Simone Lamb

Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with…

Healthcare Services

Manipur Liquor Tragedy: Toll Hits 15 as 300+ Treated for Suspected Methanol Poisoning

November 21, 2026 Simone Lamb

Up to 15 people have died and more than 300 have sought care in Imphal after drinking spurious liquor in Manipur's Chandel district. What we…

Pharmaceutical

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label

November 21, 2026 Simone Lamb

The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn…

Pharmaceutical

FHD-909 Discontinued: Foghorn and Lilly End SMARCA2 Program

October 2, 2026 Simone Lamb

FHD-909 discontinued: Foghorn and Lilly will not advance the SMARCA2 inhibitor after Phase 1 data, and Foghorn is cutting about 40% of its workforce.

Pharmaceutical

Survodutide Weight Loss: Up to 13.1% in Phase III Trial

October 1, 2026 Simone Lamb

Survodutide weight loss reached up to 13.1% versus 3.1% on placebo at 76 weeks in the Phase III SYNCHRONIZE-2 trial in people with type 2 diabetes.

Pharmaceutical

Trevogrumab Preserves Muscle During Semaglutide Weight Loss

October 1, 2026 Simone Lamb

Trevogrumab added to semaglutide cut lean muscle loss in Regeneron's nearly 1,000-patient trial, preserving over 70% of thigh muscle at 52 weeks.

Pharmaceutical

Yutrepia Patent Ruling: Liquidia Plunges After Court Loss

October 1, 2026 Simone Lamb

Yutrepia patent ruling: a Delaware court found Liquidia's Yutrepia infringes two valid United Therapeutics patent claims, and Liquidia shares plunged.

Uncategorized

Global Artificial Organs Market to Reach USD 63.31 Billion by 2035, Growing at 8.2% CAGR

September 30, 2026 Simone Lamb

FOR IMMEDIATE RELEASE — September 30, 2026 | Source: Acumen Research and Consulting Global Artificial Organs Market to Reach USD 63.31 Billion by 2035, Growing at 8.2% CAGR The global…

Uncategorized

FDA Approves Rejoni’s Juveena Hydrogel System for Preventing Intrauterine Adhesions

September 30, 2026 Simone Lamb

The U.S. Food and Drug Administration has granted Premarket Approval to the Juveena Hydrogel System, a device developed by Rejoni, Inc. to reduce the formation and recurrence of intrauterine adhesions…

Medical Device

Siemens Healthineers Launches Accela Radiotherapy System

September 30, 2026 Simone Lamb

Siemens Healthineers unveiled the Accela radiotherapy system at ASTRO 2026, claiming multi-site SBRT in as little as 60 seconds. FDA 510(k) is pending.

Uncategorized

FDA Approves Mirum’s Atebrioz for Ultra-Rare Fibrodysplasia Ossificans Progressiva

September 30, 2026 Simone Lamb

The U.S. Food and Drug Administration has approved Atebrioz (zilurgisertib), a once-daily oral therapy developed by Mirum Pharmaceuticals, for the treatment of fibrodysplasia ossificans progressiva in patients aged 12 years…

Uncategorized

Anthropic Says Claude Helped Discover a Previously Unknown CRISPR-Like Enzyme System

September 26, 2026 Simone Lamb

Anthropic says Claude agents helped identify ART, a previously uncharacterized CRISPR-like repeat system in bacteriophages, after autonomously scanning 1.9 billion protein clusters, though the system's actual biological function remains unknown.

Uncategorized

Anthropic and OpenEvidence Launch Free Medical AI for Doctors Across About 100 Countries

September 24, 2026 Simone Lamb

Anthropic and OpenEvidence are partnering to bring free, locally adapted clinical decision-support AI to doctors across roughly 100 low- and middle-income countries, building on pilot work in Rwanda and Botswana…

Posts pagination

1 … 31 32 33 … 36

You missed

Pharmaceutical

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label

November 21, 2026 Simone Lamb
Clinical Trials

India’s First Zika Vaccine Wins CDSCO Panel Nod for Phase I Trial

November 21, 2026 Simone Lamb
Clinical Trials

Rezatapopt Ovarian Cancer Data: p53 Pill Shrinks Tumours in 48% of Platinum-Resistant Patients

November 21, 2026 Simone Lamb
Clinical Trials

GLP-1 Heart Failure Study: Semaglutide and Tirzepatide Remodel Weak Hearts Beyond Weight Loss

November 21, 2026 Simone Lamb
MedGadget.in logo – medical technology news and healthcare technology insights

Proudly powered by WordPress | Theme: NewsTwenty by Themeansar.

  • Home
  • About Us
  • Author
  • Contact Us